NEW YORK – Eisbach Bio and MD Anderson Cancer Center on Tuesday announced a research collaboration to jointly discover and develop drugs focused on synthetic lethal targets.
Eisbach, based in Munich, will collaborate with experts within MD Anderson's therapeutics discovery division and Institute for Applied Cancer Science to identify targets and develop small-molecule therapies. The company will also use its discovery platform and allosteric assay technology to identify targets and develop drugs that cause DNA damage and block repair pathways.
"Our platform identifies the unique activation mechanisms of molecular machines essential for cancer cell growth," Eisbach CSO Andreas Ladurner said in a statement. "With this insight, we are able to develop targeted drugs that selectively interfere with the ignition of the engines that tumor cells have come to rely upon. These drugs are safe and selective by design."
For any therapies identified by this collaboration, Eisbach and MD Anderson will jointly decide the appropriate pathway for future development and possible commercialization. The partners did not disclose the financial details of the deal.